Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years 
Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Oil Prices Hit Four-Month High as Geopolitical Risks and Supply Disruptions Intensify 
Lotte Corporation, a South Korean multinational company that is also the fifth-largest chaebol in the country, is buying a Bristol-Myers Squibb bio facility in Syracuse, New York. Based on the reports, the sale deal is worth $160 million.
Bristol Myers Squibb is an American multinational pharmaceutical company, and it will be unloading its manufacturing plant in Syracuse. Its sale to Lotte Corporation also includes all the equipment in the facility.
Moreover, all the workers in the plant will also be continued to be employed after the sale, and this is part of the deal. This means that they will all be transferred and will start working under the said Korean company. Lotte is looking to close the acquisition deal within this year.
According to Korea Joongang Daily, Lotte Group’s board of directors approved the purchase of Bristol-Myers Squibb just late last week. The acquisition is part of the company’s preparations for the establishment of its own biopharmaceutical subsidiary called the Lotte Biologics.
It was previously reported that Lotte had already filed to trademark the said name with the Korea Intellectual Property Rights Information Service in April. Lotte's second-growth team head, Lee Won Jik, said that since the Syracuse plant has been producing drugs for a long time now, it would be easy for them to operate it once they take over.
Lotte will be upgrading the plant and renovating it as specified in the contract development and manufacturing organization (CDMO) orders. Once the contract is sealed and Lotte Biologics starts operating, it will be manufacturing $220 million worth of bioproducts over three years for Bristol-Myers Squibb. Lotte is also planning to develop its own medicines in the future.
“The East Syracuse site has been an important part of our company’s history and our manufacturing network for many decades, and we are confident that LOTTE will fully leverage the facility, its capabilities and its experienced workforce as it continues to play a vital role for patients around the world,” Bristol Myers Squibb’s Global Product Development’s executive vice president, Karin Shanahan, said in a press release.
She added, “We have taken a thoughtful approach to this decision and are confident this will best support the continued evolution of our manufacturing network and our mission to deliver innovative medicines that help patients prevail over serious diseases.”
